KORU Medical Systems (KRMD)

• Market cap: $190M
• 1 day: 1.22%
• 5 days: 1.97%
• 1 month: 4.81%
• 3 months: 62.35%
• 6 months: 57.41%
• Year to date: 6.43%
• 1 year: 95.28%
• 5 years: -33.65%
• 10 years: 4.28%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Employees: 82

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $20K | Put options by funds: $10K

3.86% less ownership

Funds ownership: 31.72% [Q2] → 27.86% (-3.86%) [Q3]

9% less capital invested

Capital invested by funds: $38.5M [Q2] → $34.9M (-$3.59M) [Q3]

17% less funds holding

Funds holding: 65 [Q2] → 54 (-11) [Q3]

54% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 24

67% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 15

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3.50 15% downside
• Avg. target: $4.63 12% upside
• High target: $6 45% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Craig-Hallum Chase Knickerbocker 48% 1-year accuracy 12 / 25 met price target	45% upside $6	Buy Maintained	17 Jan 2025
Lake Street Frank Takkinen 53% 1-year accuracy 10 / 19 met price target	21% upside $5	Buy Maintained	14 Jan 2025
Canaccord Genuity Caitlin Cronin 67% 1-year accuracy 8 / 12 met price target	3% downside $4	Buy Maintained	14 Nov 2024
Piper Sandler Jason Bednar 42% 1-year accuracy 15 / 36 met price target	15% downside $3.50	Overweight Maintained	14 Nov 2024